The Intersection of Biotech x High Tech ...

<p>Drug discovery has doubled the flow of candidates, but approvals remain roughly flat. The constraint is development, not discovery. </p><p>In this episode, a16z General Partner, Jorge Conde talks with Formation Bio cofounder and CEO Ben Liu about building a modern pharma compa ... Show More

<p>Josh Weiner left Meta to return to CVS Health with two painful realizations: consumers don't manage their health—they expect it, and the healthcare market fundamentally violates every principle of economics. In this conversation with a16z's Julie Yoo, the CVS Senior VP explain ... Show More

<p>For the first time in human history, we can diagnose thousands of genetic diseases—often for under $1,000—but we still can't treat most of them. The problem isn't understanding what's broken; it's delivering the fix to the right cells.</p><p>Eric Kelsic, CEO of Dyno Therapeuti ... Show More

Co-host Michael Chui talks with business professor Ethan Mollick. He is an associate professor at the Wharton School at the University of Pennsylvania. Mollick covers topics including the following: What is generative AI? How substantial are the performance improvements workers c ... Show More

There is a revolution unfolding in biotech. The confluence of new biological methods like CRISPR, virtually unlimited computational capacity, and machine learning has fundamentally transformed our ability to engineer biology for wide-ranging applications. Andreessen Horowitz, or ... Show More

<p><a href='https://mcdn.podbean.com/mf/web/w5aftmmy3fux99mq/Episode_32_Beam_bio.pdf'>Dr. Andy Beam</a> has trained models, mentored scientists, and used data to quantify the value of treatments. In this episode of NEJM AI Grand Rounds, Raj Manrai turns the table on his co-host, ... Show More

In this episode of Gradient Dissent, Kanjun Qiu, CEO and Co-founder of Imbue, joins host Lukas Biewald to discuss how AI agents are transforming code generation and software development. Discover the potential impact and challenges of creating autonomous AI systems that can write ... Show More

Parinaz Sobhani joins us to discuss the cutting-edge work of Georgian, a collaborative company that helps start-ups implement and scale machine learning and AI. In this episode you will learn: Parinaz’s work at Georgian [5:35] Use cases of Georgian’s work [14:35] Tools and ap ... Show More

Greg Meyers, chief digital and technology officer at Bristol Myers Squibb, explains how AI is transforming pharmaceutical research from hypothesis-driven hunches to data-driven discoveries. Learn how the company is using computational chemistry to engineer breakthrough therapies ... Show More

GSK’s Chief Digital and Technology Officer Shobie Ramakrishnan discusses how the company is leveraging AI and data models for vaccine development and drug discovery in this episode of Bloomberg Intelligence’s Tech Disruptors podcast. BI’s Health-Care Analyst Sam Fazeli and Techno ... Show More

<p>In this episode, we delve into how DeepMind's newest iteration of the AlphaFold model is revolutionizing the field of drug discovery. Explore the breakthroughs and potential applications that this cutting-edge technology brings to the pharmaceutical world.</p> <p><br>Invest in ... Show More

<p>In this episode of NEJM AI Grand Rounds, hosts Raj Manrai and Andy Beam interview <a href='https://larrysummers.com/'>Larry Summers</a> about artificial intelligence’s transformative potential and its implications for society. The conversation explores Summers’ perspective on ... Show More

Andrej Karpathy joins Sarah and Elad in this week of No Priors. Andrej, who was a founding team member of OpenAI and former Senior Director of AI at Tesla, needs no introduction. In this episode, Andrej discusses the evolution of self-driving cars, comparing Tesla and Waymo’s app ... Show More